A novel orally available small molecule that inhibits hepatitis B virus expression
Open accessThe DOI matches its Crossref record.
Abstract
Background & Aims The hallmarks of chronic HBV infection are a high viral load (HBV DNA) and even higher levels (>100-fold in excess of virions) of non-infectious membranous particles containing the tolerogenic viral S antigen (HBsAg). Currently, standard treatment effectively reduces viremia but only rarely results in a functional cure (defined as sustained HBsAg loss). There is an urgent need to identify novel therapies that reduce HBsAg levels and restore virus-specific immune responsiveness in patients. We report the discovery of a novel, potent and orally bioavailable small molecule inhibitor of HBV gene expression (RG7834). Methods RG7834 antiviral characteristics and selectivity against HBV were evaluated in HBV natural infection assays and in a urokinase-type plasminogen activator/severe combined immunodeficiency humanized mouse model of HBV infection, either alone or in combination with entecavir. Results Unlike nucleos(t)ide therapies, which reduce viremia but do not lead to an effective reduction in HBV antigen expression, RG7834 significantly reduced the levels of viral proteins (including HBsAg), as well as lowering viremia. Consistent with its proposed mechanism of action, time course RNA-seq analysis revealed a fast and selective reduction in HBV mRNAs in response to RG7834 treatment. Furthermore, oral treatment of HBV-infected humanized mice with RG7834 led to a mean HBsAg reduction of 1.09 log 10 compared to entecavir, which had no significant effect on HBsAg levels. Combination of RG7834, entecavir and pegylated interferon α-2a led to significant reductions of both HBV DNA and HBsAg levels in humanized mice. Conclusion We have identified a novel oral HBV viral gene expression inhibitor that blocks viral antigen and virion production, that is highly selective for HBV, and has a unique antiviral profile that is clearly differentiated from nucleos(t)ide analogues. Lay summary We discovered a novel small molecule viral expression inhibitor that is highly selective for HBV and unlike current therapy inhibits the expression of viral proteins by specifically reducing HBV mRNAs. RG7834 can therefore potentially provide anti-HBV benefits and increase HBV cure rates, by direct reduction of viral agents needed to complete the viral life cycle, as well as a reduction of viral agents involved in evasion of the host immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Therapeutic strategies for hepatitis B virus infection: towards a cure
Fanning, G. C., Zoulim, F., Hou, J., & Bertoletti, A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0037-0 · Cited by 557
Hepatitis B virus biology and life cycle
Tsukuda, S., & Watashi, K. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104925 · Cited by 376
Cornberg, M., Lok, A. S.-F., Terrault, N. A., Zoulim, F., Berg, T., Brunetto, M. R., Buchholz, S., Buti, M., Chan, H. L. Y., Chang, K.-M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.003 · Cited by 366
Self-citationPhenotypic drug discovery: recent successes, lessons learned and new directions
Vincent, F., Nueda, A., Lee, J., Schenone, M., Prunotto, M., & Mercola, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00472-w · Cited by 348
Host-Directed Antiviral Therapy
Kumar, N., Sharma, S., Kumar, R., Tripathi, B. N., Barua, S., Ly, H., & Rouse, B. T. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00168-19 · Cited by 271
A tale of non-canonical tails: gene regulation by post-transcriptional RNA tailing
Yu, S., & Kim, V. N. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0246-8 · Cited by 142
Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells
Nagpal, N., Wang, J., Zeng, J., Lo, E., Moon, D. H., Luk, K., Braun, R. O., Burroughs, L. M., Keel, S. B., Reilly, C., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.03.016 · Cited by 105
“PAPD5 has recently been implicated in the pathogenesis of chronic hepatitis B virus (cHBV) infection (Mueller et al., 2018).”
BackgroundMethodInfluentialChabrolles, H., Auclair, H., Vegna, S., Lahlali, T., Pons, C., Michelet, M., Couté, Y., Belmudes, L., Chadeuf, G., Kim, Y., et al. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008593 · Cited by 48
RNA stability enhancers for durable base-modified mRNA therapeutics
Jung, S.-J., Seo, J. J., Lee, S., Hyun, S.-I., Lee, J.-E., Lee, S., Lee, Y., Chang, H., Lee, H., Kim, J.-H., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02891-7 · Cited by 26
Metadata
- Authors
- Mueller, H., Wildum, S., Luangsay, S., Walther, J., Lopez, A., Tropberger, P., Ottaviani, G., Lu, W., Parrott, N. J., Zhang, J. D., Schmucki, R., Racek, T., Hoflack, J.-C., Kueng, E., Point, F., Zhou, X., Steiner, G., Lütgehetmann, M., Rapp, G., Volz, T., Dandri, M., Yang, S., Young, J. A. T., & Javanbakht, H.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 68
- Issue
- 3
- Pages
- 412-420
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2766427799
- Cited by
- 132
- References
- 0
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.